The Readout Loud

STAT
  • 0,0 (0)
  • AFFAIRES
  • CHAQUE SEMAINE

STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.

  1. 18/12/2025

    382: Biotech's year in review

    Is the biotech industry truly out of its slump? Why are employers dropping coverage of weight loss drugs? And what will the hosts bake for the holidays? We discuss all that and more on this week's episode of "The Readout LOUD," the last episode of the year. We bring on Bruce Booth, partner at venture capital firm Atlas Venture, to reflect on everything that's happened in the biotech industry this year and to look ahead at the trends next year.We also chat about Adam's picks for best and worst biopharma CEOs in 2025, and why Eli Lilly and Novo Nordisk's direct-to-consumer offerings may be contributing to employers' decisions to drop coverage of weight loss drugs.

    34 min

  2. 11/12/2025

    381: The future of American science and a dispatch from ASH

    How did Terns Pharmaceuticals and its “hodgepodge” pipeline grab attention at the American Society of Hematology conference? Is Eli Lilly’s new drug making people lose too much weight? And what, exactly, is the Trump administration’s plan for reforming the National Institutes of Health? First, we discuss all things ASH, particularly Tern’s chronic myeloid leukemia data,  Johnson & Johnson’s multiple myeloma data, and Fulcrum Therapeutics’ pill for sickle cell disease. We also get into the latest news in — what else? — obesity drugs. Then, STAT reporters Megan Molteni and Anil Oza join for a conversation on the new series “American Science, Shattered,” which details this fissure and what it means for the future of the country’s scientific institutions.

    33 min

  3. 04/12/2025

    380: A new top drug regulator and the future of psychedelics

    On this week’s episode of "The Readout Loud": a look at an emerging class of psychedelic drugs that may treat depression, anxiety, and other psychiatric conditions without the hallucinogenic “trip.” Plus, a dash through the week’s biotech news. Our special guest this week is David Olson, director of the UC Davis Institute for Psychedelics and Neurotherapeutics and the co-founder of Delix Therapeutics, a startup that is developing a new class of neuropsychiatric medicines that are similar to psychedelics in that they can exert strong and rapid therapeutic benefits, but without the hallucinogenic effects.

    33 min

  4. 20/11/2025

    379: How Mark Cuban plans to ‘f— up’ health care

    How much time does Mark Cuban spend thinking about health care? Why does he think TrumpRx, a direct drug purchasing platform that the Trump administration aims to launch, is “the most incredible program ever”? And what are his thoughts on sports betting? We discuss all that and more on this week’s episode of “The Readout LOUD,” STAT’s weekly biotech podcast. Cuban comes on for an extensive chat about the latest biosimilar launch by his company, Cost Plus Drugs, as well his broader thoughts on the drug industry and how the direct-to-consumer field is changing.We also chat about the news this week, including more M&A deals and an upcoming Alzheimer’s readout from Novo Nordisk.

    37 min

  5. 13/11/2025

    378: Merck's heart disease win and the FDA's new drug regulator

    What does Rick Pazdur's new role mean for the Food and Drug Administration? Has Merck solved the PCSK9 access issue? And how much credit can the president take for lowering GLP-1 drug prices? Dean Li, the head of R&D at Merck, joins us to discuss the long-awaited trial results for the company's oral medicine targeting PCSK9 to lower cholesterol. These types of treatments have proven effective at addressing heart disease, but making them into more accessible pills has proven tricky.We also discuss the latest news in the life sciences, including the resolution of Pfizer and Novo Nordisk's bidding war over Metsera, Pazdur's new role at the FDA, and the end of a decade-long longevity venture.

    36 min

  6. 06/11/2025

    377: Melodrama at the FDA and the Pfizer-Novo bidding war

    On a jam-packed show, your co-hosts, minus the vacationing Allison DeAngelis, chat with STAT’s D.C. correspondent Lizzy Lawrence about a slow-boiling feud between Vinay Prasad, the head of the FDA’s biologics and vaccine branch, and his staff that has triggered even more exits and plunging morale. On the drug side of the agency, we dish on the shocking exit of director George Tidmarsh after he was accused of using his regulatory position to exact personal revenge against a former business partner. Bonus: Prasad and Tidmarsh hate each other.

    31 min

  7. 30/10/2025

    376: BridgeBio’s great week and Moderna’s unraveling

    Has BridgeBio’s business model worked? How are executives at Moderna dealing with the company’s slump? And who will the hosts dress up as for Halloween? We discuss all that on this week’s episode of the “The Readout LOUD,” STAT’s biotech podcast. We bring on BridgeBio CEO Neil Kumar to discuss the company’s positive Phase 3 readouts and our colleague Jason Mast to discuss Moderna’s struggles following its Covid-19 vaccine boom.

    38 min

  8. 23/10/2025

    375: Startups push the FDA and biotech booms in North Carolina

    Can Trump take credit for North Carolina's booming biopharma industry? Which drugs could get a shortcut to the market? And who wore a tuxedo to the STAT Summit? We discuss all that and more in the latest episode of "The Readout LOUD."Elaine is out this week, so Adam and Allison dive into the latest news in the life science industry together, including the two companies pushing the Food and Drug Administration, the first recipients of the Commissioner’s National Priority Review voucher, and why Flagship Pioneering founder Nobuar Afeyan thinks that mRNA vaccines are the canary in the coal mine that is the drug industry. Adam also asks Allison about her trip to North Carolina to check out the local biomanufacturing boom.

    29 min
Tout afficher (386)

Hôtes et personnes invitées

À propos

STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.

Informations

  • Chaîne
    STAT
  • Création
    STAT
  • Années d’activité
    2018 - 2025
  • Épisodes
    386
  • Classification
    Tous publics
  • Copyright
    © All rights reserved
  • Site web de l’émission
    The Readout Loud

Plus de contenus par STAT

Vous aimeriez peut‑être aussi